COVID–19 Emergency Production Act

Summary

COVID-19 Emergency Production Act This bill directs the President to use existing authorities under the Defense Production Act of 1950 with respect to the production of COVID-19 (i.e., coronavirus disease 2019) supplies, such as personal protective equipment, diagnostic tests, and vaccines. That act confers upon the President a broad set of authorities to influence domestic industry in order to provide essential materials and goods needed for the national defense. Specifically, the President must (1) make a determination that such supplies are essential for the national defense, (2) identify private-sector capacity to produce these supplies, and (3) exercise authorities under the act to require emergency production of them at a reasonable price. In addition, the President shall coordinate the allocation of these supplies based on requests from governors and the needs of the states as determined by the population of each state. The bill's directive to produce COVID-19 supplies terminates when there are no remaining requests for them from states, and supplies that have been produced but are unused at that time shall be deposited into the Strategic National Stockpile.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 26 May 2020

   Introduced

   Introduced in House

   Source: IntroReferral

2. 26 May 2020

   Introduced

   Introduced in House

   Source: IntroReferral

3. 26 May 2020

   Introduced

   Referred to the House Committee on Financial Services.

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in House · 26 May 2020 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 26 May 2020

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 26 May 2020

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 26 May 2020

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Pocan, Mark [D-WI-2] · D · Sponsor
• Sen. Blunt Rochester, Lisa [D-DE] · D · Sponsor
• Rep. Crist, Charlie [D-FL-13] · D · Sponsor
• Rep. Cicilline, David N. [D-RI-1] · D · Cosponsor
• Rep. Jayapal, Pramila [D-WA-7] · D · Cosponsor
• · hsba00 · Standing

Related records

• related to ← COVID–19 Vaccine Distribution and Production Act